Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD
Authors
Keywords
-
Journal
EYE
Volume 28, Issue 5, Pages 538-545
Publisher
Springer Nature
Online
2014-04-11
DOI
10.1038/eye.2014.64
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab
- (2013) Arghavan Almony et al. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
- VISUAL AND ANATOMICAL OUTCOMES OF INTRAVITREAL AFLIBERCEPT IN EYES WITH PERSISTENT SUBFOVEAL FLUID DESPITE PREVIOUS TREATMENTS WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- (2013) Nishant Kumar et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-Related Macular Degeneration
- (2012) Peter K. Kaiser et al. OPHTHALMOLOGY
- Macular Epiretinal Brachytherapy in Treated Age-related Macular Degeneration
- (2012) Pravin U. Dugel et al. OPHTHALMOLOGY
- Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration
- (2012) Michael Larsen et al. OPHTHALMOLOGY
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
- (2012) Daniel F. Martin et al. OPHTHALMOLOGY
- Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
- (2012) Usha Chakravarthy et al. OPHTHALMOLOGY
- Macular Epiretinal Brachytherapy in Treated Age-related Macular Degeneration (MERITAGE)
- (2012) Robert Petrarca et al. OPHTHALMOLOGY
- Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for Recalcitrant Neovascular Macular Degeneration–Primary End Point
- (2012) David M. Brown et al. OPHTHALMOLOGY
- Variants in the VEGFA Gene and Treatment Outcome after Anti-VEGF Treatment for Neovascular Age-related Macular Degeneration
- (2012) Farshad Abedi et al. OPHTHALMOLOGY
- CURRENT KNOWLEDGE AND TRENDS IN AGE-RELATED MACULAR DEGENERATION
- (2012) Raul Velez-Montoya et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation
- (2011) Julie L Gasperini et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?
- (2011) Susanne Binder BRITISH JOURNAL OF OPHTHALMOLOGY
- Myositis Ossificans
- (2011) Deborah A. Martin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
- (2010) Dimitrios Karagiannis Clinical Interventions in Aging
- COMPARISON OF INTRAVITREAL BEVACIZUMAB FOLLOWED BY RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- (2009) KIMBERLY E. STEPIEN et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started